Latest Information Update: 22 Mar 2010
At a glance
- Originator Bayer
- Mechanism of Action Progesterone receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 09 May 2002 BAY 399624 is available for exclusive licensing in Germany [email: Arndt.Brandes.AB@bayer-ag.de]
- 04 Sep 2000 New profile
- 04 Sep 2000 Phase-I clinical trials for Postmenopausal osteoporosis in Germany (Unknown route)